The short answer
VESPER is the clinical programme for berobenatide (PF-08653944, formerly MET-097i), Pfizer's ultra-long-acting GLP-1 receptor agonist. Six trials carry the VESPER name in company communications, ranging from Phase 2b to Phase 3; the registry tells a slightly different story about which of those names are formally registered.
Key facts
- Compound
- Berobenatide (INN)
- Development codes
- PF-08653944, PF'3944, formerly MET-097 / MET-097i
- Originator
- Metsera, acquired by Pfizer 13 November 2025
- Phase 2b trials
- VESPER-1, VESPER-2, VESPER-3
- Phase 3 trials registered
- VESPER-4, VESPER-5, and NCT07595549
- Largest registered trial
- VESPER-4, 3,578 participants (estimated)
- Latest primary completion
- 4 May 2028 (NCT07595549)
- Stated programme size
- 10 Phase 3 studies planned in 2026
What the registry actually contains
Searching the registry by intervention returns a coherent programme, and it is set out here because company communications and registry records use different names for the same studies. VESPER-1 (NCT06712836) is a Phase 2 trial of 239 participants, completed, with primary completion 3 July 2025. VESPER-2 (NCT06897202) is Phase 2, 133 participants, completed, primary completion 29 December 2025. VESPER-3 (NCT06973720) is Phase 2, 268 participants, primary completion 16 December 2025, and is registered as a study of once-weekly switching to once-monthly dosing. VESPER-4 (NCT07311850) is Phase 3 with an estimated 3,578 participants and primary completion 21 September 2027.
The two Phase 3 trials whose acronyms are not registered
Two more Phase 3 records exist and neither carries a registered acronym, which is a small thing that causes real confusion. NCT07400653 has an official title ending '(VESPER-5)' - the name is present in the free-text title but the structured acronym field is empty, so the trial does not surface when you search the registry by that name. It is a Phase 3 trial of 1,044 participants in people with overweight or obesity and type 2 diabetes, with primary completion 12 October 2027. NCT07595549 is a Phase 3 trial of 954 participants that began recruiting on 10 June 2026 with primary completion 4 May 2028; press coverage calls it VESPER-6, and the registry record carries that name in neither the acronym field nor the title. If you are trying to verify a claim about 'VESPER-6', that is why you cannot find it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the trial sizes tell you where the programme is
The step from Phase 2b to Phase 3 here is a factor of thirteen: 268 participants in VESPER-3, 3,578 in VESPER-4. That is not unusual for obesity, where the safety database has to be large enough to characterise uncommon events and regulators expect a substantial exposure population. It does mean the informative efficacy data available today comes from studies of a few hundred people, and the pivotal evidence does not exist yet. Primary completion for the first Phase 3 is September 2027.
What the programme is testing that others are not
The distinguishing design feature is the dosing schedule. VESPER-3's registered title describes weekly dosing switching to monthly: four regimens of twelve weekly doses of MET097, with or without titration, followed by multiple monthly doses, against a placebo arm on the same schedule. The primary endpoint is percent change in body weight at week 28. No approved GLP-1 receptor agonist is dosed monthly, so the question the programme exists to answer is whether the weight reduction achieved on a weekly schedule holds when the interval is stretched fourfold.
What has been reported so far
Pfizer reported VESPER-3 topline on 3 February 2026: placebo-adjusted weight loss at week 28 of up to 12.3% on the efficacy estimand with a 4.8 mg monthly dose, and 10.5% on the treatment-policy estimand for that arm. A separate arm reported 10% and 8.4% on the same pair of estimands. From VESPER-1's Part B extension, 15.9% non-placebo-adjusted mean weight loss at 32 weeks on the top weekly dose. From VESPER-2, HbA1c fell 2.2 percentage points on the 1.6 mg weekly dose against 0.2 on placebo. Every one of those numbers comes from a Phase 2b study of a few hundred people, and none of them is pivotal evidence.
What this means for anyone reading about it
Berobenatide is not licensed anywhere, for anything. It is an investigational compound in Phase 3 development with first approvals discussed for 2028 at the earliest. It is not supplied here in any form and there is no research material corresponding to it on this site. It is covered because the monthly-dosing question is the most interesting open engineering problem in the class, and because a reader trying to check a claim about it should be able to find the registry numbers in one place.
Quick reference
| Trial | Registration | Phase | Enrolment | Primary completion |
|---|---|---|---|---|
| VESPER-1 | NCT06712836 | 2 | 239 | 3 July 2025 |
| VESPER-2 | NCT06897202 | 2 | 133 | 29 December 2025 |
| VESPER-3 | NCT06973720 | 2 | 268 | 16 December 2025 |
| VESPER-4 | NCT07311850 | 3 | 3,578 (est.) | 21 September 2027 |
| VESPER-5 (title only) | NCT07400653 | 3 | 1,044 (est.) | 12 October 2027 |
| No registered acronym | NCT07595549 | 3 | 954 (est.) | 4 May 2028 |
Frequently asked questions
Is VESPER-6 a real trial?
A real trial exists: NCT07595549, Phase 3, 954 participants, recruiting since 10 June 2026. Whether it is 'VESPER-6' depends on your source. Press coverage uses that name and the registry record does not, in either the acronym field or the official title. The trial is real; the name is a company designation that has not been entered into the registry.
Why does VESPER-5 not show up when I search for it?
Because registry search matches the structured acronym field, and NCT07400653's acronym field is empty even though its official title ends with '(VESPER-5)'. Searching the intervention name (berobenatide, PF-08653944 or MET097) finds it. This is a recurring problem with sponsor acronyms and it is why any claim attached to an acronym should be traced back to an NCT number.
How does 3,578 participants compare with other obesity Phase 3 trials?
It is a normal size for a pivotal obesity programme. The number is set less by what is needed to detect a weight difference, which is easy because the effect is large, than by the safety database regulators expect before approving a chronically dosed drug in a large population.
Is berobenatide available to buy?
No. It is investigational, not licensed in any jurisdiction, and not supplied on this site. Anything sold anywhere under that name would not be the compound in these trials.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialVESPER-1 registry record (NCT06712836)clinicaltrials.gov
- TrialVESPER-3 registry record (NCT06973720)clinicaltrials.gov
- TrialVESPER-4 registry record (NCT07311850)clinicaltrials.gov
- TrialVESPER-5 registry record (NCT07400653)clinicaltrials.gov
- TrialPhase 3 registry record (NCT07595549)clinicaltrials.gov
- RefPfizer: ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing, 3 February 2026pfizer.com
- RefPfizer: robust Phase 2b efficacy and favorable tolerability support monthly dosing, 6 June 2026pfizer.com
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- SOLIS-1: Testing Two Compounds and Their Combination at OnceSOLIS-1 is a Phase 2b umbrella study of an estimated 872 participants, testing an amylin analogue, an ultra-long-acting GLP-1 agonist, and both in combination.
- Reading Deal Structure as a Statement About EvidencePfizer paid $65.60 a share for Metsera plus a CVR of up to $20.65 tied to three milestones. That structure encodes how uncertain the buyer thought the data was.
- The Gap Is Smaller Outside the Trial, and It Widens With TimeA 2,396-patient US cohort found a 2.32-point weight difference at six months. The head-to-head trial found 6.5 points at 72 weeks. Both figures are right.
- Which Drug Signals Where, and What That Is WorthA 2026 FAERS analysis compared semaglutide, liraglutide and tirzepatide across gastrointestinal, renal and pancreatic outcomes. The pattern is not uniform.
- Two Phase 3 Trials, 4,700 Participants, and One Missing AcronymStructure Therapeutics dosed the first patients in its aleniglipron Phase 3 programme in July 2026. Both trials are registered; only one carries its own name.